Three-Year Durability of Automated Insulin Delivery Therapy in Children and Adolescents with Type 1 Diabetes: A Multicenter Real-World Study
Authors' conclusion
MiniMed 780G provides sustained glycemic control over 3 years. However, progressive reliance on automated corrections and reduced user engagement may attenuate tight glycemic control
Study context
- Population
- Youth with T1D (median age 12.2 years, 50.9% female) from 20 Italian pediatric diabetes centers
- Participants
- 359 participants20 Italian centres
- Outcome
- Long-term effectiveness (glucose metrics) of MiniMed 780G
- Follow-up
- 1, 2 and 3 years
Main finding
As reported in the abstract
Median TIR · 1 year to 3 years
- Median time in range (TIR) at 1 year
- 75%
- Median TIR at 3 years (modest decline, within international targets)
- 74%
- Change in TIR from 1 to 3 years
- P = 0.002
Observational data: associations, not effects.
Further findings
Predictors of achieving TITR ≥50% · 3 years
| OR (95% CI) | P value | ||
|---|---|---|---|
| Higher SmartGuard useMultivariable logistic regression · independently associated | 1.13 (1.03–1.23) | P = 0.007 | |
| Optimal system settingsMultivariable logistic regression · independently associated | 3.21 (1.33–7.77) | P = 0.010 | |
| Lower automatic correction bolusesMultivariable logistic regression · independently associated | 0.84 (0.80–0.89) | P < 0.001 | |
| 0.10.31310Odds ratio (log scale) |
Bolus patterns over time · over 3 years
- Automatic correction boluses increased; user-initiated boluses and carbohydrate entries declined
- P < 0.001
- Higher TIR at 1 year: progressive TIR reduction and greater increase in automated corrections (time × group interaction)
- P < 0.001
Original publication
Three-Year Durability of Automated Insulin Delivery Therapy in Children and Adolescents with Type 1 Diabetes: A Multicenter Real-World Study. Diabetes Technol Ther. Published 17 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →